Correlation of clinical and pathologic factors with rising prostate- specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer

Urology

Volumn 48, Issue 2, 1996, Pages 249-260

  Kupelian, Patrick ^a   Katcher, Jerald ^a   Levin, Howard ^a   Zippe, Craig ^a   Klein, Eric ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STATISTICS; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0030218881     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00167-7     Document Type: Article

References (25)

1. 1. Frazier HA, Robertson JE, Humphrey PA, and Paulson DF: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 149: 516-518, 1993.
2. 2. Oesterling J: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
3. 3. Partin A, Yoo J, Carter H, Pearson J, DW C, Epstein J, and Walsh P: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114, 1993.
4. 4. International Union Against Cancer: Urological tumours: prostate, in TNM Classification of Malignant Tumours. New York, Springer-Verlag, 1987, pp 141-144.
5. 5. Harris E, and Albert A: Survivorship Analysis for Clinical Studies. New York, Marcel Dekker, 1991.
6. 6. Partin AW, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 20: 713-725, 1993.
7. 7. Ravery V, Delmas V, Boccon-Gibod L, Meulemans A, Dauge-Geffroy M, Toublanc M, Billebaud T, and Boccon-Gibod L: Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 44: 371-376, 1994.
8. 8. D'Amico A, Whittington R, Malkowicz S, Schultz D, Schnall M, Tomaszewski J, and Wein A: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 154: 131-138, 1995.
9. 9. Zagars G, and von Eschenbach A: Prognostic factors in prostate cancer: prostate specific antigen: an important marker for prostate cancer treated by external beam radiotherapy. Cancer 72: 538-548, 1993.
10. 10. Kaplan I, Cox R, and Bagshaw M: Prostate specific antigen: after external beam radiotherapy for prostate cancer: follow-up. J Urol 149: 519-522, 1993.
11. 11. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, and Oesterling JE: Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 11: 2158-2166, 1993.
12. 12. Zietman A, Coen J, Shipley W, Willett C, and Efrid J: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate-specific antigen value as a predictor of treatment outcome. J Urol 151: 640-645, 1994.
13. 13. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, and Kinsella TJ: Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 10: 1208-1217, 1992.
14. 14. Ohori M, Wheeler T, Kattan M, Goto Y, and Scardino P: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154: 1818-1824, 1995.
15. 15. Paulson D: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 152: 1826-1830, 1994.
16. 16. Epstein J, Pizov G, and Walsh P: Correlation of pathologic findings with progression following radical prostatectomy. Cancer 71: 3582-3593, 1993.
17. 17. Epstein JI, Carmichael M, Partin AW, and Walsh PC: Is tumor volume an independent predictor of progression following radical prostatectomy? a multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow-up. J Urol 149: 1478-1481, 1993.
18. 18. Epstein JI: Evaluation of radical prostatectomy capsular margins of resection: the significance of margins designated as negative, closely approaching, and positive. Am J Surg Pathol 14: 626-632, 1990.
19. 19. Catalona W, and Bigg S: Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 143: 538-544, 1990.
20. 20. Stamey T, Villers A, McNeal J, Link P, and Freiha F: Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol 143: 166-173, 1990.
21. 21. Ackerman D, Barry J, Wicklund R, Olson N, and Lowe B: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 150: 1845-1850, 1993.
22. 22. Zincke H, Oesterling J, Blute M, Bergstralh E, Myers R, and Barrett D: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152: 1850-1857, 1994.
23. 23. Weldon V, Tavel F, Neuwirth H, and Cohen R: Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 151: 1565-1569, 1994.
24. 24. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, and Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer: the Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154: 424-428, 1995.
25. 25. Rosen MA, Goldstone L, Lapin S, Wheeler T, and Scardino PT: Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 148: 331-337, 1992.